Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2018

14.08.2018 | Review – Cancer Research

MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance

verfasst von: Maria Luisa Gasparri, Zein Mersini Besharat, Ammad Ahmad Farooqi, Sumbul Khalid, Katayoun Taghavi, Raad Aris Besharat, Claudia Sabato, Andrea Papadia, Pierluigi Benedetti Panici, Michael David Mueller, Elisabetta Ferretti

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is a leading cause of death among gynecologic malignancies. This disappointing prognosis is closely related to intrinsic or acquired resistance to conventional platinum-based chemotherapy, which can affect a third of patients. As such, investigating relevant molecular targets is crucial in the fight against this disease. So far, many mutations involved in ovarian cancer pathogenesis have been identified. Among them, a few pathways were implicated. One such pathway is the P13K/AKT/mTOR with abnormalities found in many cases. This pathway is considered to have an instrumental role in proliferation, migration, invasion and, more recently, in chemotherapy resistance. Many miRNAs have been found to influence P13K/AKT/mTOR pathway with different potential role in tumor genesis and ovarian cancer behaviour. In particular, their biological function was recently investigated as regards chemoresistance, therefore, leading to the identification of potential specific indirect biomarker of platinum sensitivity in ovarian cancer.
Literatur
Zurück zum Zitat Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L (2016) PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol 310:9–19CrossRef Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L (2016) PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol 310:9–19CrossRef
Zurück zum Zitat Bast RC, Mills GB, Dissecting (2012) “PI3Kness”: the complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16–18CrossRef Bast RC, Mills GB, Dissecting (2012) “PI3Kness”: the complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16–18CrossRef
Zurück zum Zitat Borst P, Rottenberg S, Jonkers J (2008) How do real tumors become resistant to cisplatin? Cell Cycle 7(10):1353–1359CrossRef Borst P, Rottenberg S, Jonkers J (2008) How do real tumors become resistant to cisplatin? Cell Cycle 7(10):1353–1359CrossRef
Zurück zum Zitat Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657CrossRef Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657CrossRef
Zurück zum Zitat Cornelison R, Llaneza DC, Landen CN (2017) Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. Int J Mol Sci 18(10):2171CrossRef Cornelison R, Llaneza DC, Landen CN (2017) Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. Int J Mol Sci 18(10):2171CrossRef
Zurück zum Zitat Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin W, Chen Z, Ning Y (2017) Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ov Res 10(1):50CrossRef Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin W, Chen Z, Ning Y (2017) Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ov Res 10(1):50CrossRef
Zurück zum Zitat Dobbin ZC, Landen CN (2013) The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 14(4):8213–8227CrossRef Dobbin ZC, Landen CN (2013) The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 14(4):8213–8227CrossRef
Zurück zum Zitat Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, Javed Z, Jabeen S, Yaylim I, Gasparri ML, Panici PB (2016) Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology? Chem Biol Drug Design 87(3):321–334CrossRef Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, Javed Z, Jabeen S, Yaylim I, Gasparri ML, Panici PB (2016) Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology? Chem Biol Drug Design 87(3):321–334CrossRef
Zurück zum Zitat Folgiero V, Miele E, Carai A, Ferretti E, Alfano V, Po A, Bertaina V, Goffredo BM, Benedetti MC, Camassei FD (2016) IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget 7(33):52900–52911CrossRef Folgiero V, Miele E, Carai A, Ferretti E, Alfano V, Po A, Bertaina V, Goffredo BM, Benedetti MC, Camassei FD (2016) IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget 7(33):52900–52911CrossRef
Zurück zum Zitat Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586(9):1279–1286CrossRef Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586(9):1279–1286CrossRef
Zurück zum Zitat Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Panici PB (2017a) PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? Geburtshilfe Frauenheilkd 77(10):1095CrossRef Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Panici PB (2017a) PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? Geburtshilfe Frauenheilkd 77(10):1095CrossRef
Zurück zum Zitat Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Panici PB (2017b) Beyond circulating microRNA biomarkers: urinary microRNAs in ovarian and breast cancer. Tumor Biol 39(5):1010428317695525CrossRef Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Panici PB (2017b) Beyond circulating microRNA biomarkers: urinary microRNAs in ovarian and breast cancer. Tumor Biol 39(5):1010428317695525CrossRef
Zurück zum Zitat Gasparri ML, Besharat ZM, Besharat RA, Ruscito I, Nirgianakis K, Farooqi AA, Papadia A, Ferretti E, Benedetti Panici P, Mueller DM (2018) Current knowledge of miRNAs as biomarkers in breast cancer. Springer, New York, ISBN 978-3-319-71552-0 Gasparri ML, Besharat ZM, Besharat RA, Ruscito I, Nirgianakis K, Farooqi AA, Papadia A, Ferretti E, Benedetti Panici P, Mueller DM (2018) Current knowledge of miRNAs as biomarkers in breast cancer. Springer, New York, ISBN 978-3-319-71552-0
Zurück zum Zitat Guo P, Xiong X, Zhang S, Peng D (2016) miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep 36(6):3552–3558CrossRef Guo P, Xiong X, Zhang S, Peng D (2016) miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep 36(6):3552–3558CrossRef
Zurück zum Zitat Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W (2017) A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem 41(3):973–986CrossRef Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W (2017) A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem 41(3):973–986CrossRef
Zurück zum Zitat Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926–1945CrossRef Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926–1945CrossRef
Zurück zum Zitat Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen H-IH, Chang Y-F, Panneerdoss S, Zoghi B (2012) Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7(12):e52397CrossRef Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen H-IH, Chang Y-F, Panneerdoss S, Zoghi B (2012) Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7(12):e52397CrossRef
Zurück zum Zitat Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 109(9):djx030CrossRef Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 109(9):djx030CrossRef
Zurück zum Zitat Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C (2016) Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res 76(24):7194–7207CrossRef Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C (2016) Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res 76(24):7194–7207CrossRef
Zurück zum Zitat Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG (2017) The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer 17(1):65CrossRef Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG (2017) The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer 17(1):65CrossRef
Zurück zum Zitat Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS (2011) MicroRNA signature of cisplatin resistant vs. cisplatin sensitive ovarian cancer cell lines. J Ov Res 4(1):17CrossRef Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS (2011) MicroRNA signature of cisplatin resistant vs. cisplatin sensitive ovarian cancer cell lines. J Ov Res 4(1):17CrossRef
Zurück zum Zitat Kuznetsov VA, Tang Z, Ivshina AV (2017) Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genom 18(6):692CrossRef Kuznetsov VA, Tang Z, Ivshina AV (2017) Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genom 18(6):692CrossRef
Zurück zum Zitat Mabuchi S, Kuroda H, Takahashi R, Sasano T (2015) The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol 137(1):173–179CrossRef Mabuchi S, Kuroda H, Takahashi R, Sasano T (2015) The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol 137(1):173–179CrossRef
Zurück zum Zitat Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22(15):3120–3125CrossRef Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22(15):3120–3125CrossRef
Zurück zum Zitat Montero JC, Chen X, Ocaña A, Pandiella A (2012) Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 11(6):1342–1352CrossRef Montero JC, Chen X, Ocaña A, Pandiella A (2012) Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 11(6):1342–1352CrossRef
Zurück zum Zitat Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24(2):447–463CrossRef Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24(2):447–463CrossRef
Zurück zum Zitat Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609CrossRef Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609CrossRef
Zurück zum Zitat Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101CrossRef Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101CrossRef
Zurück zum Zitat von Strandmann EP, Reinartz S, Wager U, Müller R (2017) Tumor–host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer 3(2):137–148CrossRef von Strandmann EP, Reinartz S, Wager U, Müller R (2017) Tumor–host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer 3(2):137–148CrossRef
Zurück zum Zitat Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR (2013) MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem 114(7):1464–1473CrossRef Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR (2013) MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem 114(7):1464–1473CrossRef
Zurück zum Zitat Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man X, Wei F, Yu X (2016) Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 33(11):126CrossRef Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man X, Wei F, Yu X (2016) Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 33(11):126CrossRef
Zurück zum Zitat Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y (2014) MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33(3):378CrossRef Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y (2014) MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33(3):378CrossRef
Zurück zum Zitat Xu S, Fu G-B, Tao Z, OuYang J, Kong F, Jiang B-H, Wan X, Chen K (2015) MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget 6(28):26457PubMedPubMedCentral Xu S, Fu G-B, Tao Z, OuYang J, Kong F, Jiang B-H, Wan X, Chen K (2015) MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget 6(28):26457PubMedPubMedCentral
Zurück zum Zitat Yang L, Li N, Wang H, Jia X, Wang X, Luo J (2012) Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 28(2):592–600CrossRef Yang L, Li N, Wang H, Jia X, Wang X, Luo J (2012) Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 28(2):592–600CrossRef
Zurück zum Zitat Yu X, Zheng H, Chan MT, Wu WK (2017) Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res 7(9):1769PubMedPubMedCentral Yu X, Zheng H, Chan MT, Wu WK (2017) Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res 7(9):1769PubMedPubMedCentral
Zurück zum Zitat Zhang J, Liu L, Sun Y, Xiang J, Zhou D, Wang L, Xu H, Yang X, Du N, Zhang M (2016) MicroRNA-520 g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget 7(18):26516PubMedPubMedCentral Zhang J, Liu L, Sun Y, Xiang J, Zhou D, Wang L, Xu H, Yang X, Du N, Zhang M (2016) MicroRNA-520 g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget 7(18):26516PubMedPubMedCentral
Zurück zum Zitat Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ, Cui S (2016) MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget 7(33):53254CrossRef Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ, Cui S (2016) MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget 7(33):53254CrossRef
Zurück zum Zitat Zheng W, Feng Q, Liu J, Guo Y, Gao L, Li R, Xu M, Yan G, Yin Z, Zhang S (2017) Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer. Front Pharmacol 8:421CrossRef Zheng W, Feng Q, Liu J, Guo Y, Gao L, Li R, Xu M, Yan G, Yin Z, Zhang S (2017) Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer. Front Pharmacol 8:421CrossRef
Zurück zum Zitat Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21CrossRef Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21CrossRef
Metadaten
Titel
MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance
verfasst von
Maria Luisa Gasparri
Zein Mersini Besharat
Ammad Ahmad Farooqi
Sumbul Khalid
Katayoun Taghavi
Raad Aris Besharat
Claudia Sabato
Andrea Papadia
Pierluigi Benedetti Panici
Michael David Mueller
Elisabetta Ferretti
Publikationsdatum
14.08.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2737-y

Weitere Artikel der Ausgabe 12/2018

Journal of Cancer Research and Clinical Oncology 12/2018 Zur Ausgabe

Original Article – Cancer Research

Presence and activity of HPV in primary lung cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.